Patents by Inventor Lawrence G. Hamann

Lawrence G. Hamann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
    Patent number: 6995183
    Abstract: Compounds are provided having the formula (I) wherein: n is 0, 1 or 2; m is 0, 1 or 2; the sum of n+m less then or equal to 2; the dashed bonds forming a cyclopropyl ring can only be present when Y is CH; X is H or CN; Y is CH, CH2, CHF, CF2, O, S, SO, or SO2; and A is adamantyl. Further provided are methods of using such compounds for the treatment of diabetes and related diseases, and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: July 27, 2004
    Date of Patent: February 7, 2006
    Assignee: Bristol Myers Squibb Company
    Inventors: Lawrence G. Hamann, Ashish Khanna, Mark S. Kirby, David R. Magnin, Ligaya M. Simpkins, James C. Sutton, Jeffrey Robl
  • Glycinenitrile-based inhibitors of dipeptidyl peptidase IV and methods
    Patent number: 6995180
    Abstract: A compound of the formula I: wherein R1, R2, R3 and R4 are as defined herein. Further provided are methods of using such compounds for the treatment of diabetes and related diseases, and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: October 21, 2003
    Date of Patent: February 7, 2006
    Assignee: Bristol Myers Squibb Company
    Inventors: David R. Magnin, Lawrence G. Hamann
  • N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase
    Patent number: 6846836
    Abstract: Compounds having the formula (I), are useful as inhibitors of mitochondrial F1F0 ATP hydrolase, wherein R1-R8, X, A, Z, n and m are defined herein.
    Type: Grant
    Filed: April 18, 2003
    Date of Patent: January 25, 2005
    Assignee: Bristol-Myers Squibb Company
    Inventors: Lawrence G. Hamann, Andrew T. Pudzianowski
  • Glycinenitrile-based inhibitors of dipeptidyl peptidase IV and methods
    Publication number: 20040259919
    Abstract: A compound of the formula I: 1
    Type: Application
    Filed: October 21, 2003
    Publication date: December 23, 2004
    Inventors: David R. Magnin, Lawrence G. Hamann
  • Fluorinated trienes and their use as rxr modulators
    Publication number: 20040248919
    Abstract: The present invention relates to a method of modulating retinoid X receptor activity in a mammal, novel compounds and pharmaceutical compositions for modulating retinoid X receptor activity in a mammal, and methods of making compounds that modulate retinoid X receptor activity in a mammal. The compounds are represented by Structural Formula 1: The compounds of Structural Formual 1 are efficacious insulin sensitizers and do not have the undesirable side effects of increasing triglycerides or suppressing the thyroid hormone axis.
    Type: Application
    Filed: April 15, 2004
    Publication date: December 9, 2004
    Inventors: Michael Gregory Bell, Timothy Alan Grese, Douglas Linn Gernett, Nathan P. Yumibe, Marcus F. Boehm, Pierre-Yves Michellys, Robert J. Ardecky, Christopher M Mapes, Jyun-Hung Chen, John S. Tyhonas, Lawrence G. Hamann
  • N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase
    Publication number: 20040209821
    Abstract: Compounds having the formula (I), 1
    Type: Application
    Filed: April 18, 2003
    Publication date: October 21, 2004
    Inventors: Lawrence G. Hamann, Andrew T. Pudzianowski
  • Steroid receptor modulator compounds and methods
    Publication number: 20040186132
    Abstract: Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.
    Type: Application
    Filed: December 17, 2003
    Publication date: September 23, 2004
    Inventors: Todd K. Jones, Mark E. Goldman, Charlotte L. F. Pooley, David T. Winn, James P. Edwards, Sarah J. West, Christopher M. Tegley, Lin Zhi, Lawrence G. Hamann, Luc J. Farmer, Robert L. Davis
  • RXR modulators with improved pharmacologic profile
    Publication number: 20040049072
    Abstract: The present invention provides a novel class of RXR modulator compounds that exhibit an improved pharmacologic profile relative to the profile of previously studied RXR modulators, including those that share common structural features with the presently claimed modulators. The present invention also provides synthetic methods for preparing these compounds as well as pharmaceutical compositions incorporating these novel compounds and methods for the therapeutic use of such compounds and pharmaceutical compositions.
    Type: Application
    Filed: May 9, 2003
    Publication date: March 11, 2004
    Inventors: Robert J. Ardecky, Marcus F. Boehm, Amy L. Faulkner, Lawrence G. Hamann, Todd K. Jones, Christopher M. Mapes, Pierre-Yves Michellys, John S. Tyhonas
  • (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase
    Publication number: 20040039033
    Abstract: Compounds having the formula (I), and pharmaceutically acceptable salts thereof, 1
    Type: Application
    Filed: December 10, 2002
    Publication date: February 26, 2004
    Inventors: Karnail S. Atwal, Gary J. Grover, Charles Z. Ding, Philip D. Stein, John Lloyd, Saleem Ahmad, Lawrence G. Hamann, David Green, Francis N. Ferrara
  • Steroid receptor modulator compounds and methods
    Patent number: 6696459
    Abstract: Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.
    Type: Grant
    Filed: October 14, 1997
    Date of Patent: February 24, 2004
    Assignee: Ligand Pharmaceuticals Inc.
    Inventors: Todd K. Jones, Mark E. Goldman, Charlotte L. F. Pooley, David T. Winn, James P. Edwards, Sarah J. West, Christopher M. Tegley, Lin Zhi, Lawrence G. Hamann, Luc J. Farmer, Robert L. Davis
  • Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase
    Publication number: 20040009972
    Abstract: Compounds having the formula (I), 1
    Type: Application
    Filed: June 13, 2003
    Publication date: January 15, 2004
    Inventors: Charles Z. Ding, Lawrence G. Hamann, Philip D. Stein, Andrew T. Pudzianowski
  • 8-substituted-6-triflouromethyl-9-pyrido [3,2-G] quinoline compounds as androgen receptor modulators
    Patent number: 6667313
    Abstract: Non-steroidal compounds and compositions which are agonists, partial agonists, and antagonists for androgen receptors and methods of preparation for the non-steroidal compounds and compositions.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: December 23, 2003
    Assignee: Ligand Pharmaceuticals Inc.
    Inventors: Lawrence G. Hamann, James Kong, James P. Edwards
  • 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators
    Publication number: 20030149268
    Abstract: Non-steroidal compounds and compositions which are agonists, partial agonists, and antagonists for androgen receptors and methods of preparation for the non-steroidal compounds and compositions.
    Type: Application
    Filed: December 23, 2002
    Publication date: August 7, 2003
    Inventors: Lawrence G. Hamann, James Kong, James P. Edwards
  • RXR modulators with improved pharmacologic profile
    Patent number: 6593493
    Abstract: The present invention provides a novel class of RXR modulator compounds that exhibit an improved pharmacologic profile relative to the profile of previously studied RXR modulators, including those that share common structural features with the presently claimed modulators. The present invention also provides synthetic methods for preparing these compounds as well as pharmaceutical compositions incorporating these novel compounds and methods for the therapeutic use of such compounds and pharmaceutical compositions.
    Type: Grant
    Filed: September 14, 2000
    Date of Patent: July 15, 2003
    Assignee: Ligand Pharmaceuticals, Inc.
    Inventors: Robert J. Ardecky, Marcus F. Boehm, Amy L. Faulkner, Lawrence G. Hamann, Todd K. Jones, Christopher M. Mapes, Pierre-Yves Michellys, John S. Tyhonas, Anthony W. Thompson, Jyun-Hung Chen
  • Bicyclic androgen and progesterone receptor modulator compounds and methods
    Publication number: 20030130505
    Abstract: The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by AR and PR. More particularly, the invention relates to nonsteroidal compounds and compositions that are high affinity, high specificity agonists, partial agonists (i.e., partial activators and/or tissue-specific activators) and antagonists for AR and PR. Also provided are methods of making such compounds and pharmaceutical compositions, as well as critical intermediates used in their synthesis.
    Type: Application
    Filed: November 18, 2002
    Publication date: July 10, 2003
    Inventors: Lin Zhi, Christopher Tegley, Barbara Pio, Cornelis Arjan Van Oerveren, Mehrnouch Motamedi, Esther Martinborough, Sarah West, Robert Higuchi, Lawrence G. Hamann, Luc Farmer
  • Androgen receptor modulator compounds and methods
    Patent number: 6534516
    Abstract: Non-steroidal compounds that are high affinity, high selectivity modulators for androgen receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring androgen receptor agonist, partial agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the androgen receptor modulator compounds.
    Type: Grant
    Filed: November 24, 1999
    Date of Patent: March 18, 2003
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: James P Edwards, Robert Higuchi, Todd K Jones, Lawrence G Hamann
  • Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
    Patent number: 6395767
    Abstract: Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula where x is 0 or 1 and y is 0 or 1 (provided that x=1 when y=0 and x=0 when y=1); n is 0 or 1; X is H or CN; and wherein R1, R2, R3 and R4 are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, and other diseases as set out herein, employing such DP 4 inhibitor *or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity agent and/or other therapeutic agent.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: May 28, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeffrey A. Robl, Richard B. Sulsky, David J. Augeri, David R. Magnin, Lawrence G. Hamann, David A. Betebenner
  • Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
    Publication number: 20020019411
    Abstract: Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula 1
    Type: Application
    Filed: February 16, 2001
    Publication date: February 14, 2002
    Inventors: Jeffrey A. Robl, Richard B. Sulsky, David J. Augeri, David R. Magnin, Lawrence G. Hamann, David A. Betebenner
  • Intermediates for preparation of steroid receptor modulator compounds
    Patent number: 6121450
    Abstract: Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.
    Type: Grant
    Filed: October 8, 1997
    Date of Patent: September 19, 2000
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: Todd K. Jones, David T. Winn, Lawrence G. Hamann, Lin Zhi, Luc J. Farmer, Robert L. Davis
  • Androgen receptor modulator compounds and methods
    Patent number: 6017924
    Abstract: Non-steroidal compounds that are high affinity, high selectivity modulators for androgen receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring androgen receptor agonist, partial agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the androgen receptor modulator compounds.
    Type: Grant
    Filed: August 12, 1999
    Date of Patent: January 25, 2000
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: James P Edwards, Robert Higuchi, Todd K Jones, Lawrence G Hamann